About CinRx Pharma
CinRx Pharma is a Healthcare company based in Cincinnati (United States) founded in 2015. New molecular entities are developed for various therapeutic indications. CinRx Pharma has raised $83 million across 2 funding rounds. Its chief executive, as recorded, is Jonathan Isaacsohn. Its focus areas include Life Sciences, Gastroenterology, Drugs and Diversified. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
CINRX Pharma is developing NMEs in multiple therapeutic areas. The company is planning to file the IND application for its lead candidate CIN-102 (Deuterated Domperidone, a dopamine 2-receptor antagonist) for the treatment of gastroparesis by the first half of 2018. Other candidates in their pipeline include CIN-103, a novel agent for IBS-D (Idiophathic Bowel Syndrome with Diarrhoea), CIN-105 for a cardiovascular indication and CIN-101, for a dermatology indication. The company has a unique partnership with Medpace, through which the CRO will offer clinical development resources through a preferred cost relationship and will also help in making early GoNo Go decisions.
- Total Equity Funding$83M (USD)
in 2 rounds
- Latest Funding Round$73M (USD), Series B
May 2024
Funding Insights of CinRx Pharma
CinRx Pharma has successfully raised a total of $83M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $73 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $83M
- Total Rounds 2
- Last Round Series B — $73M
- First Round $10M
(Apr 2024)
All 2 funding rounds of CinRx Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $73M | Series B | – | – | – |
| Apr 2024 | $10M | Series A | – | – | – |
People of CinRx Pharma
13 people are tracked at CinRx Pharma (10 in leadership, 3 in board & advisors).
| Name | Role | Group |
|---|---|---|
Jonathan Isaacsohn | CEO & President | Leadership |
Mary Bond | Chief Translational Science Officer | Leadership |
Yuan Lu | Director, Toxicology | Leadership |
Brian Murphy | Chief Medical Officer | Leadership |
Jon Isaacsohn | Founder & CEO | Leadership |
Mackenzie L. Pater, PhD | Executive Director, Portfolio Management | Leadership |
Elizabeth Moriarity | Director Of Clinical Monitoring | Leadership |
Brian Murphy, MD, MPH, FIDSA | Chief Medical Officer | Leadership |
Jason Westerheide | Executive Director, Business Development | Leadership |
Sally Dressman | Chief Administrative Officer | Leadership |
August Troendle | Board Member | Board & advisors |
Stephen P. Ewald | Board Member | Board & advisors |
Jesse J. Geiger | Board Member | Board & advisors |
Complete people profiles for CinRx Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of CinRx Pharma
3 dated milestones of CinRx Pharma across 9 years, from founding to its latest funding, stage changes and deals.
- Founded CinRx Pharma is founded.
- Funding First funding round of $10.0M.
- Funding Latest funding round, Series B, of $73.0M.
Competitors of CinRx Pharma
CinRx Pharma has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of CinRx Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as CinRx Pharma (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cinrx Pharma
Complete news archive for CinRx Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CinRx Pharma
CinRx Pharma was founded in 2015 and raised its 1st funding round 9 years after it was founded.
CinRx Pharma is headquartered in Cincinnati, United States. It is registered at Cincinnati, Ohio, United States.
Jonathan Isaacsohn is the CEO of CinRx Pharma, as recorded in our data.
CinRx Pharma is a funded company, having raised a total of $83M across 2 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Apr 2024.
CINRX Pharma is developing NMEs in multiple therapeutic areas. The company is planning to file the IND application for its lead candidate CIN-102 (Deuterated Domperidone, a dopamine 2-receptor antagonist) for the treatment of gastroparesis by the first half of 2018. Other candidates in their pipeline include CIN-103, a novel agent for IBS-D (Idiophathic Bowel Syndrome with Diarrhoea), CIN-105 for a cardiovascular indication and CIN-101, for a dermatology indication. The company has a unique partnership with Medpace, through which the CRO will offer clinical development resources through a preferred cost relationship and will also help in making early GoNo Go decisions.